Drug Profile
Dapirolizumab pegol - Biogen/UCB
Alternative Names: Anti-CD40L Fab; Anti-CD40L Fab-PEG; BIIB 133; CD40L - Fab; CDP-7657; DZP; Peg-dapirolizumab; Pegylated anti-CD40L antibodyLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Biogen Idec; UCB
- Developer ALS Therapy Development Institute; Biogen; UCB
- Class Antibodies; Antirheumatics; Fab fragments; Polyethylene glycols
- Mechanism of Action CD40 ligand inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Systemic lupus erythematosus
- Phase II Multiple sclerosis
- No development reported Amyotrophic lateral sclerosis; Rheumatoid arthritis
Most Recent Events
- 28 Nov 2022 Dapirolizumab pegol is still in the phase III PHOENYCS GO trial for Systemic lupus erythematosus (Adjunctive treatment, In adults, In adolescents, In the elderly) in the US, Argentina, Austria, Australia, Belgium, Bulgaria, Canada, Chile, Colombia, Czech Republic, France, Germany, Greece, Hong Kong, Hungary, Italy, South Korea, Mexico, Peru, Philippines, Poland, Portugal, Romania, Serbia, Spain, Taiwan, United Kingdom (IV) (NCT04294667) (EudraCT2019-003406-27)
- 15 Feb 2022 UCB Biopharma initiates a phase III trial for Systemic lupus erythematosus (Adjunctive treatment, In adults, In adolescents, In elderly) in Belgium (EudraCT2019-003407-35)
- 15 Jul 2021 UCB initiates enrolment in a phase III open label extension trial for Systemic lupus erythematosus in Spain in July 2021 (EudraCT2019-003409-83)